The majority of breast tumors are estrogen receptor alpha positive (ER+) and are clinically treated with endocrine therapy to deprive tumor cells of estrogen using aromatase inhibitors (AI) or to target the ER using tamoxifen or fulvestrant. The gene discussed is ESR1; the disease is neoplasm.